SCHEMBL291000

SCHEMBL291000

[CH2]SCCCCCCCCC

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.53
THRB P10828 2/20 0.53
HSD17B10 Q99714 2/20 0.42
CES2 O00748 1/20 0.42
CTSL P07711 1/20 0.42
CTSB P07858 1/20 0.42
GMNN O75496 1/20 0.42
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
CYP2C9 P11712 1/20 0.42
BLM P54132 1/20 0.42
DNM1 Q05193 7/20 0.41
CA2 P00918 1/20 0.41
ALDH1A1 P00352 2/20 0.40
LMNA P02545 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
SLC22A1 O15245 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5435445 1.00 TSHR (0.53) TSHRTHRBHSD17B10CES2CTSL
SCHEMBL916768 1.00 TSHR (0.53) TSHRTHRBHSD17B10CES2CTSL
SCHEMBL291820 1.00 TSHR (0.53) TSHRTHRBHSD17B10CES2CTSL
SCHEMBL6731455 1.00 TSHR (0.53) TSHRTHRBHSD17B10CES2CTSL
SCHEMBL291923 1.00 TSHR (0.53) TSHRTHRBHSD17B10CES2CTSL
SCHEMBL8456972 1.00 TSHR (0.53) TSHRTHRBHSD17B10CES2CTSL
SCHEMBL9149670 1.00 TSHR (0.53) TSHRTHRBHSD17B10CES2CTSL
SCHEMBL290508 1.00
SCHEMBL290726 1.00
SCHEMBL292580 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183603-A1 CLEAVABLE SURFACTANTS PROMEGA CORPORATION 2023-06-15 US disclosed
US-11624041-B2 Cleavable surfactants PROMEGA CORPORATION (US) 2023-04-11 US disclosed
US-20200263110-A1 CLEAVABLE SURFACTANTS PROMEGA CORPORATION 2020-08-20 US disclosed
US-10626349-B2 Cleavable surfactants PROMEGA CORPORATION (US) 2020-04-21 US disclosed
US-20180187127-A1 CLEAVABLE SURFACTANTS JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-07-05 US disclosed
US-9816054-B2 Cleavable surfactants PROMEGA CORPORATION (US) 2017-11-14 US disclosed
EP-2266958-B1 Antiviral agent SHIONOGI & CO (JP) 2017-03-15 EP disclosed
US-20170066754-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2017-03-09 US disclosed
US-9572813-B2 Antiviral agent SHIONOGI & CO., LTD. (JP) 2017-02-21 US disclosed
EP-3042894-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2016-07-13 EP disclosed
US-20040229909-A1 Antiviral agent SHIONOGI & CO., LTD. (JP) 2004-11-18 US disclosed
US-20040127708-A1 Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity SHIONOGI & CO., LTD. (JP) 2004-07-01 US disclosed
EP-1422218-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2004-05-26 EP disclosed
EP-1375486-A1 NITROGEN-CONTAINING HETEROARYL COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2004-01-02 EP disclosed
US-20030138864-A1 Method for identifying an enzyme to design anti-cancer compounds CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-07-24 US disclosed
WO-2003043631-A2 METHOD FOR IDENTIFICATION OF TUMOR TARGETING ENZYMES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-05-30 WO disclosed
EP-1167375-A1 ERYTHROMYCIN DERIVATIVES HOKURIKU SEIYAKU CO., LTD. (JP) 2002-01-02 EP disclosed
EP-0751133-B1 Pyrimidine compound, and liquid crystal composition and liquid crystal element using the same MITSUI CHEMICALS INC (JP) 2001-09-12 EP disclosed
US-5770108-A HIGH SPEED RESPONSE, MOLECULAR ORIENTATION, HIGH CONTRAST, RECEPTIVITY MITSUI TOATSU CHEMICALS, INC. (JP) 1998-06-23 US disclosed
EP-0751133-A1 Pyrimidine compound, and liquid crystal composition and liquid crystal element using the same MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1997-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030138864-A1 Method for identifying an enzyme to design anti-cancer compounds RNASE1, GUSB, DPEP1 TSHR 4521/4885THRB 4105/4885HSD17B10 260/4885
US-20200263110-A1 CLEAVABLE SURFACTANTS SI, PRSS3, TMPRSS15 TSHR 2971/4885THRB 4021/4885HSD17B10 1911/4885
US-20040229909-A1 Antiviral agent ZC3HAV1, ZC3HAV1L, DUT TSHR 4237/4885THRB 3764/4885HSD17B10 1428/4885
US-11624041-B2 Cleavable surfactants SI, PRSS3, TMPRSS15 TSHR 2971/4885THRB 4021/4885HSD17B10 1911/4885
US-20180187127-A1 CLEAVABLE SURFACTANTS SI, PRSS3, TMPRSS15 TSHR 2971/4885THRB 4021/4885HSD17B10 1911/4885
US-10626349-B2 Cleavable surfactants SI, PRSS3, TMPRSS15 TSHR 2971/4885THRB 4021/4885HSD17B10 1911/4885
US-20040127708-A1 Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity DUT, PNP, INMT TSHR 4421/4885THRB 3003/4885HSD17B10 837/4885
US-20230183603-A1 CLEAVABLE SURFACTANTS SI, PRSS3, TMPRSS15 TSHR 2971/4885THRB 4021/4885HSD17B10 1911/4885
US-20170066754-A1 ANTIVIRAL AGENT ZC3HAV1, ZC3HAV1L, CCNI TSHR 3427/4885THRB 3798/4885HSD17B10 1765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.